drugset / Trial / NCT05915104

Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis

NCT05915104

Phase 2 Not yet recruiting 80 enrolled University of Calgary Ferring Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research study is to compare how well two formulations of budesonide (budesonide MMX \[Cortiment\] and budesonide CR \[Entocort\]) work for treating patients with microscopic colitis.

Timeline

Start
2024-01-01
Primary completion
2026-09-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 3 mg Oral
Subject Budesonide Small molecule 9 mg Oral

Indications